FDA Approves Inavolisib with Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-mutated, HR-positive, HER2-negative Advanced Breast Cancer By Ogkologos - November 20, 2024 717 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the INAVO120 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for... August 27, 2025 Reflecting On My Time As the Cancer.Net Editor in Chief May 26, 2021 2023 Highlights in Treating Genitourinary Cancers: Expert Perspectives January 24, 2024 For Advanced Prostate Cancer, Radiopharmaceutical Improves Survival June 29, 2021 Load more HOT NEWS 31-Year Breast Cancer Survivor Celebrates 100th Birthday with Drive-By Mardi Gras... Low-Dose Aspirin Could be an Alternative to Colectomy for Preventing Colorectal... A Vaccine to Treat Non-Hodgkin Lymphoma Advancing in Clinical Trials Young Mom Of Two Survived Breast Cancer, Heart Failure, And Two...
